Lafora disease is a rare, fatal genetic disorder affecting the brain, with limited treatment options and severe symptoms.

The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.

Epidermolysis Bullosa, also colloquially known as butterfly skin disease, a rare genetic condition that makes your skin very ...

Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

The U.S. Food and Drug Administration has approved Zevaskyn for patients suffering from rare, genetic skin disease recessive ...

Abeona has won FDA approval for Zevaskyn, setting up a commercial challenge to Krystal Biotech in the rare skin disease ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Patients with severe dystrophic epidermolysis bullosa, or EB, have skin so fragile, the slightest touch can lead to ...

The US Food and Drug Administration (FDA) has approved the first cell-based gene therapy for a rare genetic skin disorder.

The administration has approved 120 billion rials (some 144,000 dollars) for treating rare and hard-to-treat diseases in the ...